SCHEMBL7091085

SCHEMBL7091085

Cc1cccc(CC(NC(=O)OC(C)(C)C)c2ccc3c(c2)NC(=S)C(C)O3)c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 5/20 0.35
HPGD P15428 4/20 0.35
HTT P42858 4/20 0.35
ALDH1A1 P00352 4/20 0.35
XBP1 P17861 3/20 0.35
JAK2 O60674 3/20 0.35
LMNA P02545 3/20 0.35
S1PR4 O95977 2/20 0.35
HSP90AA1 P07900 1/20 0.35
THRB P10828 1/20 0.35
HSD17B10 Q99714 3/20 0.34
TP53 P04637 2/20 0.34
PKM P14618 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
ALOX15 P16050 1/20 0.34
S1PR1 P21453 1/20 0.34
MAPK1 P28482 1/20 0.34
KDM4E B2RXH2 2/20 0.33
RCE1 Q9Y256 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7710779 0.91 TP53 (0.40) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7087735 0.87 MC4R (0.36) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7095873 0.87 CTSS (0.42) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7704943 0.85 ALDH1A1 (0.43) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7095640 0.84 ALDH1A1 (0.37) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7090483 0.83 CTSS (0.45) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7093383 0.83 MC4R (0.41) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7711070 0.83 CACNA1B (0.40) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7708252 0.83 CTSL (0.45) NPSR1HPGDHTTALDH1A1XBP1
SCHEMBL7092472 0.82 HSD17B10 (0.37) NPSR1HPGDHTTALDH1A1XBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed